Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00756379 · ClinicalTrials.gov registry record · NA

Century Trial, a Randomized Lifestyle Modification Study for Management of Stable Coronary Artery Disease

A NA study of Coronary Artery Disease and Cardiovascular Disease, sponsored by The University of Texas Health Science Center, Houston.

Active
Registry status
NA
Development phase
1,085
Enrollment target
1
Study location

NCT00756379: Active NA study of Coronary Artery Disease and Cardiovascular Disease, sponsored by The University of Texas Health Science Center, Houston.

NCT00756379 is a NA study of Coronary Artery Disease and Cardiovascular Disease that is active but no longer recruiting, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 1,085 participants, below the 1,282-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00756379, a NA study of Coronary Artery Disease and Cardiovascular Disease, is active but no longer recruiting, sponsored by The University of Texas Health Science Center, Houston.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
1,085 participants
Enrollment target
1
Study location

Study Summary

The Century Trial is a single center Phase III randomized study sponsored by the Albert Weatherhead III Foundation and conducted by Dr. K. Lance Gould. The study hypothesis is that a combined image-treatment regimen of PET + comprehensive program of lifestyle modification and lipid lowering drugs to target lipid level will result in an improved cardiovascular risk score when compared to current standard optimal medical therapy, potentially resulting in a lower rate of death, non-fatal myocardial infarction (MI) and revascularization procedures during long term follow-up when compared with current standard of care. If our hypothesis is correct, we will not only improve our ability to prevent and treat CAD but we will also illustrate that, even with the expenses of behavioral interventions and imaging techniques, we can be very cost effective. This information may help patients at risk or with known CAD to obtain insurance coverage to prevent the disease as well as providing a more effective way of treating it.

Primary Outcome

Average Risk Score modification during 5 year follow-up and major cardiovascular clinical events of death and non-fatal myocardial infarction.

Interventions

  • OTHER Comprehensive therapy program for risk factor modification

Study Locations (1)

Texas

  • Weatherhead PET Center, Memorial Hermann Hospital TMC - Houston

Trial Details

FieldValue
Enrollment Target 1,085 participants
Start Date 2009-03-11
Est. Completion 2027-05-31
Phase NA

What the registry record for NCT00756379 still lists

NCT00756379 is an interventional study that assigns participants to a tested intervention. Its 1,085 participants enrollment target places it among the larger protocols in the corpus, below the 1,282-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (15% lower).

The record links to 4 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Comprehensive therapy program for risk factor modification is the first listed.

NCT00756379 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00756379 about?

NCT00756379 is a clinical study titled "Century Trial, a Randomized Lifestyle Modification Study for Management of Stable Coronary Artery Disease". The Century Trial is a single center Phase III randomized study sponsored by the Albert Weatherhead III Foundation and conducted by Dr. K. Lance Gould. The study hypothesis is that a combined image-treatment regimen of PET + comprehensive program of lifestyle modification and lipid lowering drugs to...

What is the current status of trial NCT00756379?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,085 participants. The study started on 2009-03-11. Estimated completion is 2027-05-31.

What conditions does trial NCT00756379 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Cardiovascular Disease, Atherosclerosis, Coronary Stenosis.

What interventions are being tested in trial NCT00756379?

The interventions under investigation include: Comprehensive therapy program for risk factor modification (OTHER).

Who is sponsoring clinical trial NCT00756379?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00756379 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00756379's enrollment target sits among peer trials

1,085 44th of 219 higher than 176 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06671483 · 1,088 participants · Phase 3

    A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

  • NCT06074068 · 1,080 participants · NA

    Father-Focused Intervention for Reducing Family Violence and Symptoms in Children

  • NCT07213804 · 1,080 participants · Phase 3

    A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

  • NCT07196722 · 1,092 participants · Phase 2

    A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00756379, the US trial registry maintained by the National Library of Medicine. NCT00756379 (large enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.